SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hay E, Gordon C, Emery P. Assessment of lupus: where are we now? Ann Rheum Dis 1993; 52: 16972.
  • 2
    Hay E, Bacon P, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 44758.
  • 3
    Liang MH, Socker S, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 110718.
  • 4
    Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al.: Disease activity in systemic lupus erythematosus: report of the consensus study group of the European workshop for rheumatology research. III. Development of a computerized clinical chart and its application to the comparison of different indices of disease activity. Clin Exp Rheumatol 1992; 10: 54954.
  • 5
    Bombardier C, Gladman D, Urowitz M, Committee on Prognosis Studies in Systemic Lupus Erythematosus. The derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 63040.
  • 6
    Press J, Palayew K, Laxer RM, Elkon K, Eddy A, Rakoff D, et al: Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis Rheum 1996; 39: 6716.
  • 7
    Font J, Cervera R, Espinosa G, Parrarés L, Ramos-Casals M, Jiménez S, et al.: Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE in adults. Ann Rheum Dis 1998; 57: 4569.
  • 8
    Barron KS, Silverman ED, Gonzales J, Reveille JD: Clinical, serologic, and immunogenetic studies in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1993; 36: 34854.
  • 9
    Janiwityanujit S, Totemchokchyakarn K, Versasertniyom O, Vanichapunto M, Vatanasuk M. Age-related differences of clinical and immunological manifestations of SLE. Asian Pac J Allergy Immunol 1995; 13: 1459.
  • 10
    Costallat LTL, Coimbra AMV. Systemic lupus erythematosus: clinical and laboratory aspects related to age at disease onset. Clin Exp Rheumatol 1994; 12: 6037.
  • 11
    Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol 1995; 35: 86672.
  • 12
    Hashimoto H, Tsuda H, Hirano T, Takasaki Y, Matsumoto T, Hirose S. Differences in clinical and immunological findings of systemic lupus erythematosus related to age. J Rheumatol 1987; 14: 497501.
  • 13
    Lehman TJ, McCurdy DK, Bernstein BH, King KK, Hanson V. Systemic lupus erythematosus in the first decade of life. Pediatrics 1989; 83: 23541.
  • 14
    Brunner HI, Feldman BM, Bombardier C, Silverman ED. The SLEDAI, SLAM and BILAG are sensitive to clinical change in disease activity in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1999; 42: 135460.
  • 15
    Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999; 26: 4907.
  • 16
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39: 3639.
  • 17
    Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus (cSLE): cumulative disease activity over time and medication use predict disease damage. Arthritis Rheum 2002; 46: 43644.
  • 18
    Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the consensus study group of the European workshop for rheumatology research. III. Development of a computerised clinical chart and its application to the comparison clinical chart and its application to the comparison of different indices of disease activity. Clin Exp Rheumatol 1992; 10: 54954.
  • 19
    Bombardieri S, Vitali C, Caponi L, Manca L, Bencivelli W. Activity criteria in systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12: S458.
  • 20
    Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the consensus study group of the European workshop for rheumatology research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992; 10: 5417.
  • 21
    Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus Erythematosus International Collaborating Clinics/American College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 80913.
  • 22
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1982; 25: 12717.
  • 23
    Kazis L, Anderson J, Meenan R. Effect sizes for interpreting changes in health status. Med Care 1989; 27: S17889.
  • 24
    Liang MH. Evaluating measurement responsiveness. J Rheumatol 1995; 22: 11912.
  • 25
    Cohen J. Statistical power analysis for the behavioral sciences. New York: Academic Press; 1977.
  • 26
    Liang MH, Larson MG, Cullen KE, Schwartz JA. Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. Arthritis Rheum 1985; 28: 5427.
  • 27
    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 30710.
  • 28
    Hook EB, Regal RR. Validity of methods to model selection weighting for model uncertainty, and small sample size. Am J Epidemiol 1997; 145: 113844.
  • 29
    Fox J. Regression diagnostics. Thousand Oaks (CA), Sage Publications; 1997.
  • 30
    SAS/STAT software: changes and enhancements through release 6.12. Cary (NC): SAS Institute; 1997.
  • 31
    Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS systems for mixed models. Cary (NC): SAS Institute; 1996.
  • 32
    Beaton DE, Hogg-Jonson S, Bombardier C. Evaluating changes in health status: reliability and responsiveness of five generic health status measures in workers with musculoskeletal diseases. J Clin Epidemiol 1997; 50: 7993.
  • 33
    Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000; 27: 66470.
  • 34
    Hawker G, Gabriel S, Bombardier C. A reliability study of the SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol 1993; 20: 65760.
  • 35
    FitzGerald JD, Grossman JM. Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients. Lupus 1999; 8: 63844.
  • 36
    Mosca M, Bencivelli W, Vitali C, Carrai P, Neri R, Bombardieri S. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 2000; 9: 44550.
  • 37
    Samsonov MY, Tilz GP, Egorova O, Reibnegger G, Balabanova RM, Nassonov EL, et al. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995; 4: 2935.
  • 38
    Caligaris-Cappio F, Bertero MT, Converso M, Stacchini A, Romagnani S, Pizzolo G. Circulating levels of soluble CD30, a marker of cell producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 1995; 13: 33943.